Genetic basis of anthracyclines cardiotoxicity: Literature review

The purpose of this review was to systematize data on molecular genetic markers of increased risk of cardiotoxic effects, as well as to search for risk and protective variants of candidate genes. Today, the therapy of malignant neoplasms is based on the use of anthracyclines – drugs of the cytostati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. Yu. Sinitsky, A. V. Tsepokina, M. V. Khutornaya, A. V. Ponasenko, A. N. Sumin
Formato:	article
Lenguaje:	RU
Publicado:	Scientific Сentre for Family Health and Human Reproduction Problems 2021
Materias:	cardiotoxicity anthracycline genetics individual risks mirna Science Q
Acceso en línea:	https://doaj.org/article/3824f05d5c5d4a4193d6bca3f450f543
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3824f05d5c5d4a4193d6bca3f450f543
record_format	dspace
spelling	oai:doaj.org-article:3824f05d5c5d4a4193d6bca3f450f5432021-11-23T06:14:46ZGenetic basis of anthracyclines cardiotoxicity: Literature review2541-94202587-959610.29413/ABS.2021-6.4.3https://doaj.org/article/3824f05d5c5d4a4193d6bca3f450f5432021-10-01T00:00:00Zhttps://www.actabiomedica.ru/jour/article/view/2971https://doaj.org/toc/2541-9420https://doaj.org/toc/2587-9596The purpose of this review was to systematize data on molecular genetic markers of increased risk of cardiotoxic effects, as well as to search for risk and protective variants of candidate genes. Today, the therapy of malignant neoplasms is based on the use of anthracyclines – drugs of the cytostatic mechanism of action. Along with their effectiveness, these drugs can have a cardiotoxic effect on cardiomyocytes by increasing the amount of reactive oxygen species and disrupting mitochondrial biogenesis. Pathological disorders lead to an increased risk of myocardial dysfunction and a number of other cardiovascular pathologies in patients receiving chemotherapy using anthracyclines. The cardiotoxic effect of anthracyclines leads to cardiomyopathy, heart failure, myocardial infarction, and thrombosis. Early detection of cardiotoxic damage leads to reducing the negative effects of these drugs due to changes in chemotherapy tactics. It is known that the risk of cardiotoxic myocardial damage is genetically determined and controlled by more than 80 genes. In this review, the description of basic molecules such as ATP-binding cassette transporters and solute carrier family (SLC transporters), carbonyl reductase, molecules of antioxidant defense, xenobiotic and iron metabolism was performed. In addition, a special attention is paid to the study of epigenetic and post-translational regulation. The available data are characterized by some inconsistency that may be explained by the ethnic differences of the studied populations. Thus, a more detailed research of various ethnic groups, gene-gene interactions between potential candidate genes and epigenetic regulation is necessary. Thus, understanding the contribution of genetic polymorphism to the development of cardiotoxicity will help to assess the individual risks of cardiovascular pathology in patients with various types of cancer, as well as reduce the risk of myocardial damage by developing individual preventive measures and correcting chemotherapy.M. Yu. SinitskyA. V. TsepokinaM. V. KhutornayaA. V. PonasenkoA. N. SuminScientific Сentre for Family Health and Human Reproduction Problemsarticlecardiotoxicityanthracyclinegeneticsindividual risksmirnaScienceQRUActa Biomedica Scientifica, Vol 6, Iss 4, Pp 27-38 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	cardiotoxicity anthracycline genetics individual risks mirna Science Q
spellingShingle	cardiotoxicity anthracycline genetics individual risks mirna Science Q M. Yu. Sinitsky A. V. Tsepokina M. V. Khutornaya A. V. Ponasenko A. N. Sumin Genetic basis of anthracyclines cardiotoxicity: Literature review
description	The purpose of this review was to systematize data on molecular genetic markers of increased risk of cardiotoxic effects, as well as to search for risk and protective variants of candidate genes. Today, the therapy of malignant neoplasms is based on the use of anthracyclines – drugs of the cytostatic mechanism of action. Along with their effectiveness, these drugs can have a cardiotoxic effect on cardiomyocytes by increasing the amount of reactive oxygen species and disrupting mitochondrial biogenesis. Pathological disorders lead to an increased risk of myocardial dysfunction and a number of other cardiovascular pathologies in patients receiving chemotherapy using anthracyclines. The cardiotoxic effect of anthracyclines leads to cardiomyopathy, heart failure, myocardial infarction, and thrombosis. Early detection of cardiotoxic damage leads to reducing the negative effects of these drugs due to changes in chemotherapy tactics. It is known that the risk of cardiotoxic myocardial damage is genetically determined and controlled by more than 80 genes. In this review, the description of basic molecules such as ATP-binding cassette transporters and solute carrier family (SLC transporters), carbonyl reductase, molecules of antioxidant defense, xenobiotic and iron metabolism was performed. In addition, a special attention is paid to the study of epigenetic and post-translational regulation. The available data are characterized by some inconsistency that may be explained by the ethnic differences of the studied populations. Thus, a more detailed research of various ethnic groups, gene-gene interactions between potential candidate genes and epigenetic regulation is necessary. Thus, understanding the contribution of genetic polymorphism to the development of cardiotoxicity will help to assess the individual risks of cardiovascular pathology in patients with various types of cancer, as well as reduce the risk of myocardial damage by developing individual preventive measures and correcting chemotherapy.
format	article
author	M. Yu. Sinitsky A. V. Tsepokina M. V. Khutornaya A. V. Ponasenko A. N. Sumin
author_facet	M. Yu. Sinitsky A. V. Tsepokina M. V. Khutornaya A. V. Ponasenko A. N. Sumin
author_sort	M. Yu. Sinitsky
title	Genetic basis of anthracyclines cardiotoxicity: Literature review
title_short	Genetic basis of anthracyclines cardiotoxicity: Literature review
title_full	Genetic basis of anthracyclines cardiotoxicity: Literature review
title_fullStr	Genetic basis of anthracyclines cardiotoxicity: Literature review
title_full_unstemmed	Genetic basis of anthracyclines cardiotoxicity: Literature review
title_sort	genetic basis of anthracyclines cardiotoxicity: literature review
publisher	Scientific Сentre for Family Health and Human Reproduction Problems
publishDate	2021
url	https://doaj.org/article/3824f05d5c5d4a4193d6bca3f450f543
work_keys_str_mv	AT myusinitsky geneticbasisofanthracyclinescardiotoxicityliteraturereview AT avtsepokina geneticbasisofanthracyclinescardiotoxicityliteraturereview AT mvkhutornaya geneticbasisofanthracyclinescardiotoxicityliteraturereview AT avponasenko geneticbasisofanthracyclinescardiotoxicityliteraturereview AT ansumin geneticbasisofanthracyclinescardiotoxicityliteraturereview
_version_	1718416876013355008

Genetic basis of anthracyclines cardiotoxicity: Literature review

Ejemplares similares